Stocks and Investing
Stocks and Investing
Fri, November 3, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, November 2, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Fein Maintained (CCCC) at Strong Buy with Decreased Target to $7 on, Nov 2nd, 2023
Andrew Fein of HC Wainwright & Co., Maintained "C4 Therapeutics, Inc." (CCCC) at Strong Buy with Decreased Target from $17 to $7 on, Nov 2nd, 2023.
Andrew has made no other calls on CCCC in the last 4 months.
There is 1 other peer that has a rating on CCCC. Out of the 1 peers that are also analyzing CCCC, all agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Chi Fong of "B of A Securities" Maintained at Hold with Decreased Target to $2 on, Monday, October 9th, 2023
Contributing Sources